{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-000928","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2021-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.180076+00:00","generated_at":"2026-06-30T02:24:46.070373+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USANA posts record Q2 sales of $336.8M (+30.1% YoY); EPS $1.87 (+41.7% YoY)","bullets":["Q2 net sales $336.8M, +30.1% YoY; diluted EPS $1.87, +41.7% YoY; active customers 652K (+8.8%).","Asia Pacific sales $279M (+33.3% YoY); Americas & Europe $57.9M (+16.5% YoY).","Gross margin improved 150bps to 83.1%; associate incentives rose 290bps to 45.7% of sales.","Repurchased 304K shares for $29.7M in Q2; $51M remaining under authorization.","FY2021 outlook reiterated: net sales $1.24-$1.28B, diluted EPS $6.15-$6.50."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-000928","json":"https://secwatch.observer/filing/0001157523-21-000928.json","markdown":"https://secwatch.observer/filing/0001157523-21-000928.md","text":"https://secwatch.observer/filing/0001157523-21-000928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752321000928/0001157523-21-000928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752321000928/a52466918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:24:46.070373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}